Similar articles

• OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity.

  Vasquez EM, Fabrega AJ, Pollak R. Vasquez EM, et al. Transplant Proc. 1995 Feb;27(1):873-4. Transplant Proc. 1995. PMID: 7879215 No abstract available.
• Cytokine-release syndrome: differences between high and low doses of OKT3.

  Norman DJ, Kimball JA, Barry JM. Norman DJ, et al. Transplant Proc. 1993 Apr;25(2 Suppl 1):35-8. Transplant Proc. 1993. PMID: 8465420 Clinical Trial. No abstract available.
• Prolonged neurological disability following OKT3 therapy for acute renal transplant rejection.

  Jeffrey RF, Johnson MH, Bamford JM, Giles GR, Brownjohn AM, Will EJ. Jeffrey RF, et al. Transplantation. 1993 Mar;55(3):677-9. Transplantation. 1993. PMID: 8456493 No abstract available.
• OKT3-induced cytokine-release syndrome: prevention effect of anti-tumor necrosis factor monoclonal antibody.

  Chatenoud L. Chatenoud L. Transplant Proc. 1993 Apr;25(2 Suppl 1):47-51. Transplant Proc. 1993. PMID: 8465425 Review. No abstract available.
• General aspects of cytokine-release syndrome: timing and incidence of symptoms.

  Jeyarajah DR, Thistlethwaite JR Jr. Jeyarajah DR, et al. Transplant Proc. 1993 Apr;25(2 Suppl 1):16-20. Transplant Proc. 1993. PMID: 8465415 Review.